Evidence map›Paper›PMID 33111200›Full record

ArticleFunctional & integrative genomics2021

Transcriptome analysis of the circadian clock gene BMAL1 deletion with opposite carcinogenic effects.

Handan Emisoglu-Kulahli, Seref Gul, Hande Morgil, Onur Ozcan, Fatih Aygenli, Saba Selvi, Ibrahim Halil Kavakli, Nuri Ozturk

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Handan Emisoglu-Kulahli *Department of Molecular Biology and Genetics, Gebze Technical University, Gebze, Kocaeli, Turkey.
Seref Gul *Department of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.
Hande MorgilDepartment of Biology, Istanbul University, Istanbul, Turkey.
Onur OzcanDepartment of Chemical and Biological Engineering, Koc University, Istanbul, Turkey.
Fatih AygenliDepartment of Molecular Biology and Genetics, Gebze Technical University, Gebze, Kocaeli, Turkey.
Saba SelviDepartment of Molecular Biology and Genetics, Gebze Technical University, Gebze, Kocaeli, Turkey.
Ibrahim Halil KavakliDepartment of Molecular Biology and Genetics, Koc University, Istanbul, Turkey.
Nuri OzturkDepartment of Molecular Biology and Genetics, Gebze Technical University, Gebze, Kocaeli, Turkey. nuriozturk@gtu.edu.tr.ORCID http://orcid.org/0000-0001-5206-4127
Gebze Technical University · TRKoç University · TRIstanbul Technical University · TR

Funding

GTÜ-BAP 2018-A-105-39Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 114S446
6 · The paper itself

Abstract

We have previously reported that the deletion of BMAL1 gene has opposite effects in respect to its contribution to the pathways that are effective in the multistage carcinogenesis process. BMAL1 deletion sensitized nearly normal breast epithelial (MCF10A) and invasive breast cancer cells (MDA-MB-231) to cisplatin- and doxorubicin-induced apoptosis, while this deletion also aggravated the invasive potential of MDA-MB-231 cells. However, the mechanistic relationship of the seemingly opposite contribution of BMAL1 deletion to carcinogenesis process is not known at genome-wide level. In this study, an RNA-seq approach was taken to uncover the differentially expressed genes (DEGs) and pathways after treating BMAL1 knockout (KO) or wild-type (WT) MDA-MB-231 cells with cisplatin and doxorubicin to initiate apoptosis. Gene set enrichment analysis with the DEGs demonstrated that enrichment in multiple genes/pathways contributes to sensitization to cisplatin- or doxorubicin-induced apoptosis in BMAL1-dependent manner. Additionally, our DEG analysis suggested that non-coding transcript RNA (such as lncRNA and processed pseudogenes) may have role in cisplatin- or doxorubicin-induced apoptosis. Protein-protein interaction network obtained from common DEGs in cisplatin and doxorubicin treatments revealed that GSK3β, NACC1, and EGFR are the principal genes regulating the response of the KO cells. Moreover, the analysis of DEGs among untreated BMAL1 KO and WT cells revealed that epithelial-mesenchymal transition genes are up-regulated in KO cells. As a negative control, we have also analyzed the DEGs following treatment with an endoplasmic reticulum (ER) stress-inducing agent, tunicamycin, which was affected by BMAL1 deletion minimally. Collectively, the present study suggests that BMAL1 regulates many genes/pathways of which the alteration in BMAL1 KO cells may shed light on pleotropic phenotype observed.

Indexed as

TranscriptomeApoptosisARNTL Transcription FactorsCarcinogenesisCell Line, TumorGene DeletionGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansARNTL Transcription FactorsBMAL1 protein, humanApoptosisBMAL1CancerCircadian clockRNA-seqTranscriptome

Identifiers

PMID33111200
OpenAlexW3096632349

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.